Axerion Therapeutics Inc.'s technology aims to block the binding of Amyloid beta to the prion protein PrP-C, a mechanism its scientists say is the toxic trigger behind neuronal death in Alzheimer's disease. Based at Yale University in New Haven, the team found that mice with AB plaques but no PrP-C showed no cognitive impairment.
[A#SC092004]
555 Long Wharf Drive
11th Floor
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
